Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective

# Background Tyrosine kinase inhibitors (TKIs) are the standard-of-care treatment for chronic myeloid leukemia in chronic phase (CML-CP). Despite advances in therapy, there remains a proportion of patients with CML-CP that are refractory/intolerant to TKIs, and these patients cycle through multiple...

Full description

Saved in:
Bibliographic Details
Main Authors: Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2022-08-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.36976
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items